Coverage
-
January 20, 2012
Drug buyer plaintiffs in a putative antitrust class action accusing Braintree Laboratories Inc. of initiating baseless patent litigation to block a generic version of the laxative MiraLax asked a Delaware federal judge Friday to approve a $17.25 million settlement of direct purchaser claims.
2 other articles on this case.
View all »